Furthermore, we find that FOS is comparatively more upregulated in the moderate-to-severe disease stage (see Figure 7), and that its upregulation is only minimally impacted by the use of hormonal therapy for both peritoneal lesions and deep infiltrating endometriosis (see Figures 4, 5). This evidence concerns the gene FOS and endometriosis.